Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
:TBPH
Total Valuation
Theravance Biopharma has a market cap or net worth of $562.51M. The enterprise value is $488.06M.
Market Cap$562.51M
Enterprise Value$488.06M
Share Statistics
Theravance Biopharma has 50,001,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50,001,330
Owned by Insiders26.91%
Owned by Institutions0.01%
Financial Efficiency
Theravance Biopharma’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -17.84%.
Return on Equity (ROE)-0.32
Return on Assets (ROA)-0.16
Return on Invested Capital (ROIC)-17.84%
Return on Capital Employed (ROCE)-0.15
Revenue Per Employee663.72K
Profits Per Employee-581.63K
Employee Count97
Asset Turnover0.18
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Theravance Biopharma is -8.15. Theravance Biopharma’s PEG ratio is 3.63.
PE Ratio-8.15
PS Ratio0.00
PB Ratio3.30
Price to Fair Value2.62
Price to FCF17.05
Price to Operating Cash Flow16.83
PEG Ratio3.63
Income Statement
In the last 12 months, Theravance Biopharma had revenue of 64.38M and earned -56.42M in profits. Earnings per share was -1.15.
Revenue64.38M
Gross Profit64.38M
Operating Income-46.95M
Pretax Income-44.61M
Net Income-56.42M
EBITDA-38.45M
Earnings Per Share (EPS)-1.15
Cash Flow
In the last 12 months, operating cash flow was 32.53M and capital expenditures -241.00K, giving a free cash flow of 32.28M billion.
Operating Cash Flow32.53M
Free Cash Flow32.28M
Free Cash Flow per Share0.65
Dividends & Yields
Theravance Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.85
52-Week Price Change29.31%
50-Day Moving Average9.38
200-Day Moving Average9.09
Relative Strength Index (RSI)68.53
Average Volume (3m)339.56K
Important Dates
Theravance Biopharma upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
Theravance Biopharma as a current ratio of 5.02, with Debt / Equity ratio of 29.01%
Current Ratio5.02
Quick Ratio5.02
Debt to Market Cap0.02
Net Debt to EBITDA-0.26
Interest Coverage Ratio-18.44
Taxes
In the past 12 months, Theravance Biopharma has paid 11.80M in taxes.
Income Tax11.80M
Effective Tax Rate-0.26
Enterprise Valuation
Theravance Biopharma EV to EBITDA ratio is -10.05, with an EV/FCF ratio of -39.75.
EV to Sales7.33
EV to EBITDA-10.05
EV to Free Cash Flow-39.75
EV to Operating Cash Flow-40.89
Balance Sheet
Theravance Biopharma has $130.85M in cash and marketable securities with $48.16M in debt, giving a net cash position of -$82.70M billion.
Cash & Marketable Securities$130.85M
Total Debt$48.16M
Net Cash-$82.70M
Net Cash Per Share-$1.65
Tangible Book Value Per Share$3.59
Margins
Gross margin is 59.08%, with operating margin of -72.92%, and net profit margin of -87.63%.
Gross Margin59.08%
Operating Margin-72.92%
Pretax Margin-69.30%
Net Profit Margin-87.63%
EBITDA Margin-72.92%
EBIT Margin-73.25%
Analyst Forecast
The average price target for Theravance Biopharma is $17.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$17.00
Price Target Upside51.11% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast6.11%
EPS Growth Forecast-37.79%